Multi-Center Phase Ib Study of Intermittent Dosing of the MEK inhibitor, Selumetinib, in Patients with advanced Uveal Melanoma Not Previously Treated with a MEK Inhibitor
Sponsor: |
AstraZeneca |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ6999 |
U.S. Govt. ID: |
NCT02768766 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to find out what effects, good and/or bad, intermittent dosing of the medication Selumetinib will have on you and your uveal melanoma. Selumetinib is a medication that blocks (or turns off) MEK, a protein activated in some uveal melanoma cells. Selumetinib is a MEK inhibitor. Blocking MEK may stop your cancer from growing.
This study is closed
Investigator
Mariam El-Ashmawy, MD, PhD
Have you been diagnosed with metastatic uveal melanoma? |
Yes |
No |
Are you able to swallow pills? |
Yes |
No |
Do you have any history of heart disease? |
Yes |
No |